Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026

Nu-3 shows rapid in vitro action, but pivotal clinical data remain over a year away.

What the company is saying

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is emphasizing new research on its lead candidate, Nu-3, presented at IDWeek 2026. The company frames Nu-3 as a novel, broad-spectrum antimicrobial with rapid bactericidal activity, highlighting its potential to address resistant pathogens in infected diabetic foot ulcers (iDFU). Management, led by CEO and SVP of R&D Kelvin Cooper, Ph.D., claims Nu-3 eradicates bacteria within minutes and maintains a low resistance profile, with only a slight increase in MIC values versus a 600- to 2,000-fold increase for ciprofloxacin. The announcement stresses the unmet need, citing that 15% to 25% of iDFUs involve resistant organisms, primarily MRSA. The tone is optimistic, focusing on Nu-3’s differentiation and the ongoing Phase 2a trial, with topline data expected in Q1 2027. The company does not reference financials or commercial partnerships, keeping the narrative tightly focused on scientific progress and future clinical milestones.

What the data suggests

The disclosed data show Nu-3 achieves broad-spectrum, rapid bactericidal activity in vitro, with bacterial eradication occurring within minutes for tested pathogens, including Gram-positive, Gram-negative, and multidrug-resistant bacteria. Serial-passage testing indicates only a slight increase in MIC for Nu-3 against Staphylococcus aureus and Escherichia coli, compared to a 600- to 2,000-fold increase for ciprofloxacin, suggesting a favorable resistance profile. The company contextualizes the unmet need by stating that 15% to 25% of infected diabetic foot ulcers involve resistant organisms, though this is epidemiological background, not company-generated data. Nu-3’s clinical progress is at the Phase 2a stage, with the trial ongoing and topline results expected in the first quarter of 2027. No efficacy, safety, or human clinical outcomes are disclosed. There are no financial metrics, revenue, or cost data provided. The evidence supports Nu-3’s potential based on preclinical and early-stage findings, but the investment case remains unproven until clinical data are available.

Analysis

The announcement is generally positive in tone, highlighting promising preclinical and early clinical data for Nu-3, including rapid bactericidal activity and low resistance development in laboratory settings. However, the majority of the claims are based on in vitro and preclinical results, with the only clinical progress being the ongoing Phase 2a trial, for which topline data are not expected until the first quarter of 2027—over a year away. The language used by management emphasizes the 'potential' of Nu-3 and its differentiation, but no efficacy or safety data from human trials are disclosed yet. There is no mention of revenue, profitability, or capital outlay, which is typical for a clinical-stage biotech but means that the investment case remains speculative until clinical results are available. The gap between narrative and evidence is moderate: the company is appropriately enthusiastic about its scientific findings, but the real-world impact and commercial viability remain unproven at this stage.

Risk flags

• ●The primary risk is clinical: Nu-3’s rapid bactericidal activity and low resistance profile are demonstrated in vitro and in preclinical models, but there is no disclosed evidence of efficacy or safety in humans. If Phase 2a results do not confirm these findings, the program could stall.
• ●Execution risk is significant, as the company must successfully complete the ongoing Phase 2a trial and generate compelling data to advance Nu-3. Delays, recruitment challenges, or negative outcomes could materially impact the development timeline and investor confidence.
• ●Financial risk is present but not quantified, as the company provides no information on cash runway, funding needs, or partnership status. Sustaining R&D through to pivotal trials will likely require additional capital, and the absence of financial disclosure leaves investors unable to assess near-term funding risk.

Bottom line

Lakewood-Amedex Biotherapeutics Inc. is advancing Nu-3, a novel antimicrobial, with promising in vitro and preclinical data showing rapid action and a low tendency for resistance, especially compared to ciprofloxacin’s 600- to 2,000-fold MIC increase. The company is targeting a significant unmet need in infected diabetic foot ulcers, where 15% to 25% of cases involve resistant organisms. However, the clinical program is still in Phase 2a, with topline data not due until Q1 2027, and no human efficacy or safety results have been disclosed. The announcement is credible in its scientific framing but offers no financial or commercial milestones, leaving the investment case speculative until clinical results are available. Investors should focus on the upcoming Phase 2a readout as the next major catalyst. The most important takeaway is that Nu-3’s real-world potential remains unproven until human data are released.

Announcement summary

(NASDAQ:LABT) Lakewood-Amedex Biotherapeutics Inc. announced the presentation of research on Nu-3, its lead clinical candidate, at IDWeek 2026. The research highlights Nu-3's broad-spectrum and rapid bactericidal activity against Gram-positive, Gram-negative, and multidrug-resistant bacteria, with bacterial eradication occurring within minutes for tested pathogens. The poster also reports activity against biofilm organisms. Serial-passage testing showed that Nu-3 had only a slight increase in minimum inhibitory concentration (MIC) values against Staphylococcus aureus and Escherichia coli, compared to a 600- to 2,000-fold increase for ciprofloxacin. The findings are relevant to infected diabetic foot ulcers (iDFU), where approximately half of diabetic foot ulcers become infected and an estimated 15% to 25% involve resistant organisms, primarily methicillin-resistant Staphylococcus aureus (MRSA). Nu-3 is currently being investigated in an ongoing Phase 2a clinical trial in patients with mildly infected diabetic foot ulcers. Topline data from the trial are expected in the first quarter of 2027. Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics, stated that the data reinforce the potential of Nu-3 to address antimicrobial resistance and underscore its potential as a differentiated antimicrobial therapy for iDFUs. The IDWeek 2026 presentation, titled 'Nu-3 – A Novel, Broad Spectrum Antimicrobial Compound with High In-Vitro Activity Against Resistant Pathogens for the Treatment of Infected Diabetic Foot Ulcers,' was scheduled for October 22, 2026, from 12:15 PM to 1:30 PM ET in Poster Hall B-C. Nu-3 is being developed for the topical treatment of mildly infected diabetic foot ulcers and belongs to the Bisphosphocin® class of antimicrobials, which possess a unique mechanism of action enabling rapid elimination of a broad spectrum of bacteria, including resistant pathogens and biofilms. Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing the Bisphosphocin® class of fast-acting, broad-spectrum antimicrobials to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA and VRE.

Disagree with this article?